Conciseness

Almost all content is non-obvious operational knowledge Claude cannot know ("Param: `query=` (NOT `target_name=`)", response-nesting paths like "data.disease.associatedTargets.rows", 403-vs-404 semantics), but there is real duplication: the USPTO_API_KEY/403 explanation appears in both the Patent Landscape Check and the Troubleshooting table, and the 10x dose-feasibility principle is stated three times ("How to Interpret" item 2, Best Practices item 4, and the dose-feasibility procedure). Efficient with trimmable repetition fits 4; it is not 5 because of this duplicated material, and not 3 because nothing explains concepts Claude already knows.

Actionability

The Quick Start is executable end-to-end with real tool names and response paths, and the tool catalog gives exact parameter names with misuse warnings ("medicinalproduct= (NOT drug_name=)", "newline-separated string, NOT array"). However, the dose-feasibility procedure is pseudocode whose parsing step is literally "pass # Parse actual values from results", so guidance is mostly but not fully executable — the 4 anchor, not 5.

Workflow Clarity

Phases 1-5 are clearly sequenced, strategy selection is required before tool use ("Identify which strategy applies FIRST"), and "How to Interpret and Combine Results" plus the Troubleshooting table provide checkpoints and error-recovery paths (e.g., "Patent tools return HTTP 403 → USPTO_API_KEY missing/invalid"). Validation is framed as interpretive questions ("Does the drug actually hit the target at achievable doses?") rather than explicit pass/fail gates mid-workflow, so it lands at 4 rather than 5's explicit validation steps and feedback loops.

Progressive Disclosure

The body signals one-level-deep references ("See: PROCEDURES.md for detailed step-by-step procedures" and a Reference Files section listing REFERENCE.md, EXAMPLES.md, PROCEDURES.md, REPORT_TEMPLATE.md), but none of these files exist in the bundle — the pointers are dead ends. Meanwhile substantial advanced content (Patent Landscape Check, LINCS/L1000FWD, NCATS Translator subsections) is inlined directly in SKILL.md. This matches the 3 anchor: structure present, references signaled but broken, and content that should be separate is inline — not 4, whose references must actually resolve.

Specificity

"Identify drug repurposing candidates via target-based, compound-based, and disease-based strategies" and "Combines drug-target-disease network reasoning with mechanism rationale, clinical-trial precedent, and patent/regulatory feasibility" enumerate multiple concrete actions in third person, covering identification, evidence integration, and prioritization with no vague filler. This matches the 5 anchor (multiple specific actions, comprehensive) rather than 4 because coverage spans the full task surface, not just a few actions with gaps.

Completeness

The what is explicit ("Identify drug repurposing candidates via ... strategies") and the when is an explicit trigger clause: "Use for hypothesis-generating repurposing for orphan diseases, finding existing drugs for new indications, and prioritizing candidates by evidence and feasibility." Both are concrete and explicit, matching the 5 anchor exactly.

Trigger Term Quality

"drug repurposing candidates", "orphan diseases", "finding existing drugs for new indications", and "prioritizing candidates" are natural user phrasings, but common synonyms such as "drug repositioning" and "off-label" are absent. Good coverage with a few natural terms missing fits the 4 anchor, below 5's comprehensive-synonym coverage.

Distinctiveness Conflict Risk

The niche is narrow and consistently named ("drug repurposing", "new indications", "orphan diseases") with nothing generic that would fire on unrelated biomedical or document skills. Fits the 5 anchor: clear niche with distinct triggers and minimal conflict risk.